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A
LTHOUGH RANDOMIZED TRIALS HAVE BEEN CON­
ducted for several decades now, some aspects of
their analysis remain contentious. Two such is­
sues are what to do about trial participants who do not
adhere to the protocol (for example, if they do not re­
ceive the intended treatment) and how to deal with
those for whom outcome assessments are missing (for
example, because they are lost to follow­up). Both of
these issues are relevant to the adoption of so­called “in­
tention to treat” (ITT) analysis – a topic that, not sur­
prisingly, also causes debate.
ITT analysis is widely recommended as the preferred
approach to analyzing the outcomes of randomized tri­
als.
1,2 In an ITT analysis, all randomized patients are in­
cluded in the analysis in their assigned groups
regardless of all considerations, including whether they
in fact received the designated intervention. ITT analys­
is should therefore compare outcomes in groups that
correspond exactly to the randomization scheme. Any
deviation from that principle may introduce bias.
An immediate problem is that some data are missing
from almost all randomized trials.
3 Clearly, just a few
missing outcomes will not be a concern, but one review
found that, in about half of randomized controlled trials
(RCTs), outcomes are missing for more than 10% of par­
ticipants.
4 A major concern is that being lost to follow­
up could be related to a patient’s response to the treat­
ment; indeed, we should assume that this will be so.
That concern can be compounded if the reasons for, or
frequency of, dropout differs between the treatment
groups.
No analysis option is ideal here; there is, in effect, a
choice between omitting participants without final out­
come data or estimating (imputing) the missing out­
come data. What should researchers do? A “complete
case” (or “available case”) analysis simply omits those
for whom data are incomplete. This commonly used ap­
proach loses power, and bias may well be introduced,
given that the incompleteness of data will not be ran­
dom. Further, excluding some patients is not compat­
ible with the ITT principle. Imputation of the missing
data allows the analysis to conform to ITT analysis but
requires strong assumptions that may be hard to justi­
fy.
5,6 However, some concerns about “making up the
data” are misplaced.
7
Methods for the imputation of missing values have
been the topic of much methodological and empirical
research in recent years. The generally preferred im­
putation methods are quite complex,
5­8 and some
simple approaches that have been around a long time
are much more popular. One of the simplest and most
commonly used of these in the analysis of continuous
outcomes is “last observation carried forward” (LOCF)
analysis, in which missing final values of the outcome
variable are replaced by the last known value before the
participant was lost to follow­up. LOCF analysis appeals
through its simplicity and ease of application, but there
are strong grounds for not using it. Specifically, the
method may introduce bias in the results, and this bias
can, according to circumstance, be in either direction.
9
Also, because in LOCF analysis no allowance is made
for the uncertainty of imputation, the resulting confid­
ence intervals are too narrow.
10
Even if missing outcomes are random across trial
participants, LOCF analysis assumes that the missing
final values would be the same as the last recorded val­
ues. That assumption is often implausible (even as an
average), because dropping out is likely to be associated
with response to treatment; obvious examples are fail­
ure to respond to treatment and adverse effects. In
practice, missing data are very likely to be related to re­
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Molnar and colleagues have discussed these issues in
the specific context of trials of dementia therapies.
9,11
They found that 34 of 57 RCTs used LOCF as the only
form of ITT analysis. Not surprisingly, that is a much
higher proportion than the 19% observed in a review of
trials across various medical specialties published in 4
general medical journals.
4
As Molnar and colleagues note,
11 their study cannot
quantify the magnitude of the effect of the use of LOCF
analysis on trial results, but it does highlight the high
prevalence of conditions for which this method of ana­
lysis could promote bias in favour of more toxic ther­
apies and against less toxic alternatives.
Their study focused on a limited number of trials con­
cerning a single medical condition, but many of the is­
sues it raises apply to all trials. It is known that most
trials include some patients whose outcomes are ulti­
mately not known, and for which an ITT analysis is not
possible without some type of imputation (although au­
thors commonly mislabel available case analyses as
ITT).
12,13
Whichever imputation approach is used, it is desir­
able to report analyses with and without imputation.
Also, it may be valuable to explore different imputation
approaches. As Molnar and colleagues suggest, “the
onus is on the investigators who publish these trials to
disprove the possibility that these analyses have intro­
duced bias by performing ITT sensitivity analyses … .
This is particularly true for those studies demonstrating
higher dropout rates in treatment groups.”
11
A further important issue is that this information
should be included in the report of a trial. The CON­
SORT (Consolidated Standards for Reporting of Trials)
Statement recommends that authors specify the meth­
ods used for all statistical analyses reported.
14 The state­
ment’s accompanying explanatory paper included
various comments on ITT analysis, but there was no spe­
cific mention of imputation.
15 Noting that omission, Sha­
piro wrote: “A variety of options are available to handle
missing data from participants who drop out of the trial
and it is important for readers to know what strategy
the investigators adopted. Without such information,
the fact that an intent­to­treat analysis was carried out
is only partially informative.”
16 That omission will be
remedied in the forthcoming 2009 update of the CON­
SORT Statement.
Transparency of reporting facilitates reliable apprais­
al of the quality and relevance of health research.
17 Suc­
cessful transparency may be judged by whether others
are able to reproduce all the methods used. The Interna­
tional Committee of Medical Journal Editors makes the
sensible recommendation to “[d]escribe statistical meth­
ods with enough detail to enable a knowledgeable read­
er with access to the original data to verify the reported
results” (http://www.icmje.org/). That is very sound ad­
vice for all research articles, not just RCTs; indeed, I see
no reason why it should not apply to all study methods.
Molnar and colleagues have gone further than Sha­
piro by suggesting that the CONSORT group should
give guidance on methods for analysing trials when
data are missing.
11 However, because the purpose of the
CONSORT group is to give guidance on the reporting of
what was done, and not to advise on what is good or
bad methodology, such guidance will not come from
that source. But, given that so many others have warned
about the dangers of LOCF analysis, it seems clear that
its use as the sole form of analysis should be discontin­
ued.
8,9,16,18,19
Finally, as Liu and colleagues observed, it is import­
ant in the design and conduct of studies to try to pre­
vent losses to follow­up and to try to minimize the bias
caused by the inevitable missing data.
20 To that end,
they provide helpful guidance for both the conduct and
reporting of RCTs where missing outcomes are likely:
• discuss at the planning stage methods and procedures
that maximize the chance of retaining patients (e.g.,
short course of rescue medicine),
• continue to collect data post‐withdrawal to preserve the
ITT population,
• document the reasons for missing data,
• anticipate and investigate the types of missing data,
• pre‐specify primary as well as sensitivity statistical ana‐
lyses,
• fully report the extent and pattern of missing data,
• support conclusions based on results from the planned
analyses with proper sensitivity assessment.
20
Adherence to this advice will lead to better design, ana­
lysis, reporting and interpretation of future trials in all
medical specialties.
References
1. Moher D, Schulz KF, Altman D. CONSORT Group. The CON­
SORT Statement: Revised recommendations for improving the
quality of reports of parallel­group randomized trials. JAMA.
2001;285(15):1987–1991.
2. Montori VM, Guyatt GH. Intention­to­treat principle. CMAJ.
2001;165(10):1339–41.
3. Altman DG, Bland JM. Missing data. BMJ. 7590;334
(7590):424.
4. Wood AM, White IR, Thompson SG. Are missing outcome data
adequately handled? A review of published randomized con­
trolled trials in major medical journals. Clin Trials.
2004;1(4):368–376.
5. Salim A, Mackinnon A, Christensen H, Griffiths K. Comparison
of data analysis strategies for intent­to­treat analysis in pre­test­
post­test designs with substantial dropout rates. Psychiatry Res.
2008;160(3):335–345.
6. Streiner DL. Missing data and the trouble with LOCF. Evid
Based Ment Health. 2008;11(1):3–5.
7. Graham JW. Missing data analysis: Making it work in the real
world. Annu Rev Psychol. 2009;60:549–576.
8. Lane P. Handling drop­out in longitudinal clinical trials: A com­
parison of the LOCF and MMRM approaches. Pharm Stat.
2008;7(2):93–106.Analysis and Comment Altman
Open Medicine 2009 3(2):51 -53
9. Molnar FJ, Hutton B, Fergusson D. Does analysis using "last ob­
servation carried forward" introduce bias in dementia research?
CMAJ. 2008;179(8):751–753.
10. Ware JH. Interpreting incomplete data in studies of diet and
weight loss. N Engl J Med. 2003;348(21):2136–2137.
11. Molnar FJ, Man­Song­Hing M, Hutton B, Fergusson D. Have
last­observation­carried­forward analyses caused us to favour
more toxic dementia therapies over less toxic alternatives? A sys­
tematic review. Open Med. 2009;3(2):1–20.
12. Hollis S, Campbell F. What is meant by intention to treat analys­
is? Survey of published randomised controlled trials. BMJ.
1999;319(7211):670–674.
13. Gravel J, Opatrny L, Shapiro S. The intention­to­treat approach
in randomized controlled trials: Are authors saying what they do
and doing what they say? Clin Trials. 2007;4(4):350–356.
14. Moher D, Jones A, Lepage L. CONSORT Group (Consolidated
Standards for Reporting of Trials). Use of the CONSORT State­
ment and quality of reports of randomized trials: A comparative
before­and­after evaluation. JAMA. 2001;285(15):1992–1995.
15. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne
D, et al. CONSORT GROUP (Consolidated Standards of Report­
ing Trials). The revised CONSORT Statement for reporting ran­
domized trials: Explanation and elaboration. Ann Intern Med.
2001;134(8):663–694.
16. Shapiro S. The revised CONSORT Statement: Honing the cutting
edge of the randomized controlled trial. CMAJ.
2001;164(8):1157–1158.
17. Altman DG, Simera I, Hoey J, Moher D, Schulz K. EQUATOR: Re­
porting guidelines for health research. Open Med.
2008;2(2):e24–e25.
18. Barnes SA, Mallinckrodt CH, Lindborg SR, Carter MK. The im­
pact of missing data and how it is handled on the rate of false­
positive results in drug development. Pharm Stat.
2008;7(3):215–225.
19. Streiner DL. The case of the missing data: Methods of dealing
with dropouts and other research vagaries. Can J Psychiatry.
2002;47(1):68–75.
20. Liu M, Wei L, Zhang J. Review of guidelines and literature for
handling missing data in longitudinal clinical trials with a case
study. Pharm Stat. 2006;5(1):7–18.
Citation: Altman DG. Missing outcomes in randomized trials:
addressing the dilemma Open Med 2009;3(2):51‐53
Published: 12 May 2009
Copyright: Open Medicine applies the Creative Commons At‐
tribution Share Alike License, which means that anyone is
able to freely copy, download, reprint, reuse, distribute,
display or perform this work and that authors retain copy‐
right of their work. Any derivative use of this work must be
distributed only under a license identical to this one and
must be attributed to the authors. Any of these conditions
can be waived with permission from the copyright holder.
These conditions do not negate or supersede Fair Use laws in
any country.